Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1984 1
1985 1
2000 2
2001 4
2002 3
2003 1
2007 1
2008 1
2009 1
2011 2
2012 1
2016 1
2017 2
2019 2
2020 1
2021 2
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial.
Mah JK, Clemens PR, Guglieri M, Smith EC, Finkel RS, Tulinius M, Nevo Y, Ryan MM, Webster R, Castro D, Kuntz NL, McDonald CM, Damsker JM, Schwartz BD, Mengle-Gaw LJ, Jackowski S, Stimpson G, Ridout DA, Ayyar-Gupta V, Baranello G, Manzur AY, Muntoni F, Gordish-Dressman H, Leinonen M, Ward LM, Hoffman EP, Dang UJ; NorthStar UK Network and CINRG DNHS Investigators. Mah JK, et al. JAMA Netw Open. 2022 Jan 4;5(1):e2144178. doi: 10.1001/jamanetworkopen.2021.44178. JAMA Netw Open. 2022. PMID: 35076703 Free PMC article. Clinical Trial.
There were no statistically significant differences between participants receiving higher-dose vamorolone and matched participants in the historical control groups receiving glucocorticoid treatment (75 patients in DNHS and 110 patients in NSUK) over a 2-year period in NSAA total …
There were no statistically significant differences between participants receiving higher-dose vamorolone and matched participants in the hi …
Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial.
McDonald CM, Shieh PB, Abdel-Hamid HZ, Connolly AM, Ciafaloni E, Wagner KR, Goemans N, Mercuri E, Khan N, Koenig E, Malhotra J, Zhang W, Han B, Mendell JR; the Italian DMD Telethon Registry Study Group, Leuven NMRC Registry Investigators, CINRG Duchenne Natural History Investigators, and PROMOVI Trial Clinical Investigators. McDonald CM, et al. Among authors: abdel hamid hz. J Neuromuscul Dis. 2021;8(6):989-1001. doi: 10.3233/JND-210643. J Neuromuscul Dis. 2021. PMID: 34120909 Free PMC article. Clinical Trial.
A Combined Prospective and Retrospective Comparison of Long-Term Functional Outcomes Suggests Delayed Loss of Ambulation and Pulmonary Decline with Long-Term Eteplirsen Treatment.
Mitelman O, Abdel-Hamid HZ, Byrne BJ, Connolly AM, Heydemann P, Proud C, Shieh PB, Wagner KR, Dugar A, Santra S, Signorovitch J, Goemans N; investigators from the LNMRC Natural History study; McDonald CM; investigators from the CINRG Duchenne National History Study; Mercuri E; investigators from The DMD Italian Group; Mendell JR. Mitelman O, et al. Among authors: abdel hamid hz. J Neuromuscul Dis. 2022;9(1):39-52. doi: 10.3233/JND-210665. J Neuromuscul Dis. 2022. PMID: 34420980 Free PMC article. Clinical Trial.
Geographical distribution and genetic diversity of Plasmodium vivax reticulocyte binding protein 1a correlates with patient antigenicity.
Park JH, Kim MH, Sutanto E, Na SW, Kim MJ, Yeom JS, Nyunt MH, Abbas Elfaki MM, Abdel Hamid MM, Cha SH, Alemu SG, Sriprawat K, Anstey NM, Grigg MJ, Barber BE, William T, Gao Q, Liu Y, Pearson RD, Price RN, Nosten F, Yoon SI, No JH, Han ET, Auburn S, Russell B, Han JH. Park JH, et al. Among authors: abdel hamid mm. PLoS Negl Trop Dis. 2022 Jun 23;16(6):e0010492. doi: 10.1371/journal.pntd.0010492. eCollection 2022 Jun. PLoS Negl Trop Dis. 2022. PMID: 35737709 Free PMC article.
Suitability of external controls for drug evaluation in Duchenne muscular dystrophy.
Goemans N, Signorovitch J, Sajeev G, Yao Z, Gordish-Dressman H, McDonald CM, Vandenborne K, Miller D, Ward SJ, Mercuri E; investigators from PRO-DMD-01 Study, CINRG DNHS, ImagingDMD, and the DMD Italian Group. Goemans N, et al. Neurology. 2020 Sep 8;95(10):e1381-e1391. doi: 10.1212/WNL.0000000000010170. Epub 2020 Jul 1. Neurology. 2020. PMID: 32611643 Free PMC article.
Combination therapy with nusinersen and AVXS-101 in SMA type 1.
Lee BH, Collins E, Lewis L, Guntrum D, Eichinger K, Voter K, Abdel-Hamid HZ, Ciafaloni E. Lee BH, et al. Among authors: abdel hamid hz. Neurology. 2019 Oct 1;93(14):640-641. doi: 10.1212/WNL.0000000000008207. Epub 2019 Sep 5. Neurology. 2019. PMID: 31488615 No abstract available.
Effectiveness of Psychotherapy in Adult ADHD: What Do Patients Think? Results of the COMPAS Study.
Groß V, Lücke C, Graf E, Lam AP, Matthies S, Borel P, Sobanski E, Rösler M, Retz W, Jacob C, Colla M, Huss M, Jans T, Kis B, Abdel-Hamid M, Tebartz van Elst L, Philipsen A; Comparison of Methylphenidate and Psychotherapy in Adult ADHD Study (COMPAS) Consortium. Groß V, et al. Among authors: abdel hamid m. J Atten Disord. 2019 Jul;23(9):1047-1058. doi: 10.1177/1087054717720718. Epub 2017 Jul 26. J Atten Disord. 2019. PMID: 28745107

RESULTS: In respect to patients' subjective ratings, ADHD-specific group psychotherapy outperformed unspecific management post-treatment ( z = 4.88, p < .0001) and at follow-up ( z = 2.90, p = .004). Rank correlations with rater-based symptom change were small to

…
RESULTS: In respect to patients' subjective ratings, ADHD-specific group psychotherapy outperformed unspecific management post-treatment ( …
Small-Molecule Inhibitors of the NusB-NusE Protein-Protein Interaction with Antibiotic Activity.
Cossar PJ, Abdel-Hamid MK, Ma C, Sakoff JA, Trinh TN, Gordon CP, Lewis PJ, McCluskey A. Cossar PJ, et al. Among authors: abdel hamid mk. ACS Omega. 2017 Jul 31;2(7):3839-3857. doi: 10.1021/acsomega.7b00273. Epub 2017 Jul 25. ACS Omega. 2017. PMID: 30023707 Free PMC article.
In contrast to representative Gram-negative Escherichia coli and Gram-positive Bacillus subtilis species, these analogues showed up to 100% growth inhibition at 200 muM. 2-((Z)-4-(((Z)-4-(4-((E)-(Carbamimidoylimino)methyl)phenoxy)but-2-en-1-yl)oxy)benzylidene)hydraz …
In contrast to representative Gram-negative Escherichia coli and Gram-positive Bacillus subtilis species, these analogues showed up to 100% …
Aflatoxin B1 level in relation to child's feeding and growth.
Shouman BO, El Morsi D, Shabaan S, Abdel-Hamid AH, Mehrim A. Shouman BO, et al. Among authors: abdel hamid ah. Indian J Pediatr. 2012 Jan;79(1):56-61. doi: 10.1007/s12098-011-0493-y. Epub 2011 Jun 4. Indian J Pediatr. 2012. PMID: 21643863
Maternal parity, education and occupation were also collected. Height for age Z-score (HAZ) and weight for age Z-score (WAZ) of children were calculated at the time of recruitment. ...Aflatoxin B1 in breastfed patients was significantly lower than in non-breastfed o …
Maternal parity, education and occupation were also collected. Height for age Z-score (HAZ) and weight for age Z-score (WAZ) o …
28 results